NEWS: 公告在東京證券交易所JASDAQ標準市場新上市

市場調查報告書

酒糟:市場洞察,流行病學,市場預測 ∼2027年

Rosacea - Market Insight, Epidemiology and Market Forecast - 2028

出版商 DelveInsight Business Research LLP 商品編碼 736690
出版日期 按訂單生產 內容資訊 英文 100 Pages
商品交期: 2-10個工作天內
價格
酒糟:市場洞察,流行病學,市場預測 ∼2027年 Rosacea - Market Insight, Epidemiology and Market Forecast - 2028
出版日期: 按訂單生產內容資訊: 英文 100 Pages
簡介

主要7個國家(美國,英國,德國,法國,義大利,西班牙,日本)的酒糟患者數在2016年為4,735萬9,758人,市場規模估計為4億9,440萬美元。

本報告提供酒糟的相關調查,疾病概要,患者背景,主要7個國家性別、各種類、重症度的患病數及診斷數,各治療藥物的市場規模的變化與預測(今後10年份),已上市藥及新藥概要,診斷指南,市場規模,市場成長要素、障礙,競爭情形等總括性彙整。

目錄

第1章 重要的洞察

第2章 酒糟:市場概要

  • 市場佔有率(成果值)
  • 市場佔有率(預測值)

第3章 疾病背景和概要

  • 簡介
  • 徵兆與症狀
  • 酒糟的分類
  • 病情和重病度
  • 病理生理學
  • 全基因組相關分析(GWAS)為基礎遺傳的背景
  • 原因和危險因素
  • 診斷

第4章 流行病學和患者人口

  • 主要的觀察

第5章 主要7個國家的總患病數

第6章 主要7個國家的總診斷數

第7章 酒糟的流行病學:各國

  • 美國
    • 前提和根據
    • 總患病數
    • 患病數:性別
    • 總診斷數
    • 診斷數:各類型
    • 診斷數:各重症度
  • 歐洲主要5個國家
    • 德國
      • 總患病數
      • 患病數:性別
      • 總診斷數
      • 診斷數:各類型
      • 診斷數:各重症度
    • 法國
      • 總患病數
      • 患病數:性別
      • 總診斷數
      • 診斷數:各類型
      • 診斷數:各重症度
    • 義大利
      • 總患病數
      • 患病數:性別
      • 總診斷數
      • 診斷數:各類型
      • 診斷數:各重症度
    • 西班牙
      • 總患病數
      • 患病數:性別
      • 總診斷數
      • 診斷數:各類型
      • 診斷數:各重症度
    • 英國
      • 總患病數
      • 患病數:性別
      • 總診斷數
      • 診斷數:各類型
      • 診斷數:各重症度
  • 日本
    • 總患病數
    • 患病數:性別
    • 總診斷數
    • 診斷數:各類型
    • 診斷數:各重症度

第8章 治療流程,現行治療,醫療行為

第9章 未滿足需求

第10章 已上市藥

  • Rhofade:Allergan
    • 藥品概要
    • 作用機制
    • 法規的里程碑
    • 產品開發趨勢
    • 優點與缺點
    • 安全性和有效性
    • 產品簡介
  • Oracea:Galderma Laboratories
  • Mirvaso:Galderma Laboratories
  • Finacea:Bayer
  • Soolantra:Galderma Laboratories, Inc.
  • Metrogel:Galderma Laboratories

第11章 Key Cross Competition

第12章 新藥

  • FMX103:Foamix Pharmaceuticals
    • 藥品概要
    • 作用機制
    • 法規的里程碑
    • 產品開發趨勢
    • 優點與缺點
    • 安全性和有效性
    • 產品簡介
  • Epsolay:Sol-Gel
  • Omiganan:Cutanea Life Sciences
  • BPX-04:BioPharmX, Inc.
  • ACU-D1:Accuitis., Inc.
  • HY01(Minocycline):Hovione Scientia Limited
  • DFD-04:Dr. Reddy's Laboratories
  • DFD-29:Dr. Reddy's Laboratories
  • DMT210:Dermata Therapeutics

第13章 市場分析主要7個國家

  • 主要的觀察
  • 主要7個國家的市場規模

第14章 美國市場預測

  • 美國的市場規模
    • 總市場規模
    • 市場規模:各治療藥物

第15章 市場預測歐洲5個國家

  • 德國
    • 總市場規模
    • 市場規模:各治療藥物
  • 法國
    • 總市場規模
    • 市場規模:各治療藥物
  • 義大利
    • 總市場規模
    • 市場規模:各治療藥物
  • 西班牙
    • 總市場規模
    • 市場規模:各治療藥物
  • 英國
    • 總市場規模
    • 市場規模:各治療藥物

第16章 日本市場預測

  • 總市場規模
  • 市場規模:各治療藥物

第17章 市場成長要素

第18章 市場障礙

第19章 附錄

  • 調查方法

第20章 DelveInsight的服務內容

第21章 免責聲明

第22章 關於DelveInsight

目錄
Product Code: DIMI0199

DelveInsight's "Rosacea - Market Insight, Epidemiology and Market Forecast - 2028" report provides a detailed analysis of the Rosacea epidemiology and market outlook for the 7MM.

Markets Covered

  • United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

Study Period: 2016-2028

Rosacea Understanding and Treatment Algorithm

The market report provides the overview of the Rosacea by providing the disease overview, definition, classification, symptoms, etiology, pathophysiology and diagnostic methods. It also covers the detailed treatment approaches and therapy areas under research and development for 7MM.

Rosacea Epidemiology

The report provides a comprehensive account of the total patient pool, diagnosed cases and potential patient pool eligible for the treatment. It also includes the explanation of changing trends of epidemiology after evaluating numerous studies, survey reports and views of key opinion leaders. The Report provides the 10 years forecast from 2016 to 2028 segmented by seven major markets, enabling to understand the potential of the Rosacea in the respective markets. The epidemiology data is presented with graphs and tables to provide a clear assessment of the landscape.

Rosacea Product Profiles & Analysis

The drug chapter segment covers the complete analysis of marketed drugs and Phase III & late Phase II pipeline drugs. This division focuses on the recent breakthroughs like clinical development analysis, agreements and collaborations, clinical trial details, allotted designations, published results, pharmacological effects, patent expiry, and expected launch timings. Moreover, advantages and disadvantages of the therapy along with opinion of experts for marketed and emerging drugs are also provided.

Rosacea Market Outlook

The report's market outlook delivers an understanding of the country-specific revenue and share by analyzing the performance of the current therapies and potential uptake of new products. The in-depth analysis helps to recognize the growing demand of the market by evaluating the annual cost of therapy, compliance rate, competition with other therapies, covered patient segment, impact of emerging technology in the forecast period. The views from the key opinion leaders adds more value to the analysis. This segment provides the relevant graphs and tables to have an effective outline of the Rosacea market.

Rosacea Market Share by Therapies

This division provides an understanding of the rate of drug uptake, drugs including both recently launched and those which show potential to get launched during the forecast period from 2016-2028. The analysis is based on patient uptake by therapies, sales projection of each drug by studying the reasons behind the maximal use of new drugs. A comparative analysis is also done on the basis of market share and size by assessing the drugs uptake to project the drug positioning in the market.

Rosacea Report Insights

  • Patient Population in Rosacea
  • Therapeutic Approaches in Rosacea
  • Rosacea Pipeline Analysis
  • Rosacea Market Size and Trends
  • Rosacea Market Opportunities
  • Impact of upcoming Therapies in Rosacea

Rosacea Report Key Strengths

  • 10 Year Forecast
  • 7MM Coverage
  • Epidemiology Segmentation
  • Drugs Uptake
  • Highly Analyzed Market
  • Key Cross Competition

Rosacea Report Assessment

  • Current Treatment Practices in Rosacea
  • Unmet Needs in Rosacea
  • Market Attractiveness
  • Market Drivers and Barriers

Key Benefits

  • The report will help to develop Business Strategies by understanding the trends shaping and driving the Rosacea market
  • Organize sales and marketing efforts by identifying the best opportunities for Rosacea market
  • To understand the future market competition in the Rosacea market.

Table of Contents

1. Report Introduction

2. Rosacea Market Overview at a Glance

  • 2.1. Market Share Distribution of Rosacea in 2016
  • 2.2. Market Share Distribution of Rosacea in 2028

3. Disease Background and Overview: Rosacea

  • 3.1. Introduction
  • 3.2. Symptoms
  • 3.3. Etiology
  • 3.4. Risk Factors
  • 3.5. Pathophysiology
  • 3.6. Diagnosis
  • 3.7. Treatment

4. Epidemiology and Patient Population

  • 4.1. Key Findings
  • 4.2. Total Prevalent/ Incident Patient Population of Rosacea in 7MM
  • 4.3. Total Prevalent Patient Population of Rosacea in 7MM - By Countries

5. Epidemiology of Rosacea by Countries

  • 5.1. United States
    • 5.1.1. Assumptions and Rationale
    • 5.1.2. Prevalent/Incident Cases of the Rosacea
    • 5.1.3. Sub-Type Specific cases of the Rosacea *
    • 5.1.4. Sex- Specific Cases of the Rosacea *
    • 5.1.5. Diagnosed Cases of the Rosacea
    • 5.1.6. Treatable Cases of the Rosacea
  • 5.2. EU5
  • 5.3. Assumptions and Rationale
  • 5.4. Germany
    • 5.4.1. Assumptions and Rationale
    • 5.4.2. Prevalent/Incident Cases of the Rosacea
    • 5.4.3. Sub-Type Specific cases of the Rosacea *
    • 5.4.4. Sex- Specific Cases of the Rosacea *
    • 5.4.5. Diagnosed Cases of the Rosacea
    • 5.4.6. Treatable Cases of the Rosacea
  • 5.5. France
    • 5.5.1. Assumptions and Rationale
    • 5.5.2. Prevalent/Incident Cases of the Rosacea
    • 5.5.3. Sub-Type Specific cases of the Rosacea *
    • 5.5.4. Sex- Specific Cases of the Rosacea *
    • 5.5.5. Diagnosed Cases of the Rosacea
    • 5.5.6. Treatable Cases of the Rosacea
  • 5.6. Italy
    • 5.6.1. Assumptions and Rationale
    • 5.6.2. Prevalent/Incident Cases of the Rosacea
    • 5.6.3. Sub-Type Specific cases of the Rosacea *
    • 5.6.4. Sex- Specific Cases of the Rosacea *
    • 5.6.5. Diagnosed Cases of the Rosacea
    • 5.6.6. Treatable Cases of the Rosacea
  • 5.7. Spain
    • 5.7.1. Assumptions and Rationale
    • 5.7.2. Prevalent/Incident Cases of the Rosacea
    • 5.7.3. Sub-Type Specific cases of the Rosacea *
    • 5.7.4. Sex- Specific Cases of the Rosacea *
    • 5.7.5. Diagnosed Cases of the Rosacea
    • 5.7.6. Treatable Cases of the Rosacea
  • 5.8. United Kingdom
    • 5.8.1. Assumptions and Rationale
    • 5.8.2. Prevalent/Incident Cases of the Rosacea
    • 5.8.3. Sub-Type Specific cases of the Rosacea *
    • 5.8.4. Sex- Specific Cases of the Rosacea *
    • 5.8.5. Diagnosed Cases of the Rosacea
    • 5.8.6. Treatable Cases of the Rosacea
  • 5.9. Japan
    • 5.9.1. Assumptions and Rationale
    • 5.9.2. Prevalent/Incident Cases of the Rosacea
    • 5.9.3. Sub-Type Specific cases of the Rosacea *
    • 5.9.4. Sex- Specific Cases of the Rosacea *
    • 5.9.5. Diagnosed Cases of the Rosacea
    • 5.9.6. Treatable Cases of the Rosacea

6. Current Treatment & Medical practices

  • 6.1. Treatment Algorithm
  • 6.2. Treatment Guidelines

7. Unmet Needs of the Rosacea

8. Marketed Therapies

  • 8.1. Drug A: Company 1
    • 8.1.1. Drug Description
    • 8.1.2. Mechanism of Action
    • 8.1.3. Regulatory Milestones
    • 8.1.4. Advantages & Disadvantages
    • 8.1.5. Product Profile
  • 8.2. Drug B: Company 2
    • 8.2.1. Drug Description
    • 8.2.2. Mechanism of Action
    • 8.2.3. Regulatory Milestones
    • 8.2.4. Advantages & Disadvantages
    • 8.2.5. Product Profile

9. Pipeline Therapies - At a glance

10. Key Cross Competition

11. Emerging Therapies for Rosacea

  • 11.1. Drug C: Company 3
    • 11.1.1. Drug Description
    • 11.1.2. Clinical Trials Details
    • 11.1.3. Safety and Efficacy Profile
    • 11.1.4. Advantages & Disadvantages
    • 11.1.5. Pipeline Development Activities
    • 11.1.6. Product Profile
  • 11.2. Drug D: Company 4
    • 11.2.1. Drug Description
    • 11.2.2. Clinical Trials Details
    • 11.2.3. Safety and Efficacy Profile
    • 11.2.4. Advantages & Disadvantages
    • 11.2.5. Pipeline Development Activities
    • 11.2.6. Product Profile

12. Rosacea : 7MM Market Analysis

  • 12.1. 7MM Market Size of Rosacea
  • 12.2. 7MM Percentage Share of drugs marketed for Rosacea
  • 12.3. 7MM Market Sales of Rosacea by Products

13. Rosacea : Country-Wise Market Analysis

  • 13.1. United States
    • 13.1.1. Market Size of Rosacea in United States
    • 13.1.2. Percentage Share of drugs marketed for Rosacea in United States
    • 13.1.3. Market Sales of Rosacea by Products in United States
    • 13.1.4. Analysis of Upcoming Therapies and their Impact on the Market
  • 13.2. EU-5
    • 13.2.1. Germany
      • 13.2.1.1. Market Size of Rosacea in Germany
      • 13.2.1.2. Percentage Share of drugs marketed for Rosacea in Germany
      • 13.2.1.3. Market Sales of Rosacea by Products in Germany
      • 13.2.1.4. Analysis of Upcoming Therapies and their Impact on the Market
    • 13.2.2. France
      • 13.2.2.1. Market Size of Rosacea in France
      • 13.2.2.2. Percentage Share of drugs marketed for Rosacea in France
      • 13.2.2.3. Market Sales of Rosacea by Products in France
      • 13.2.2.4. Analysis of Upcoming Therapies and their Impact on the Market
    • 13.2.3. Italy
      • 13.2.3.1. Market Size of Rosacea in Italy
      • 13.2.3.2. Percentage Share of drugs marketed for Rosacea in Italy
      • 13.2.3.3. Market Sales of Rosacea by Products in Italy
      • 13.2.3.4. Analysis of Upcoming Therapies and their Impact on the Market
    • 13.2.4. Spain
      • 13.2.4.1. Market Size of Rosacea in Spain
      • 13.2.4.2. Percentage Share of drugs marketed for Rosacea in Spain
      • 13.2.4.3. Market Sales of Rosacea by Products in Spain
      • 13.2.4.4. Analysis of Upcoming Therapies and their Impact on the Market
    • 13.2.5. United Kingdom
      • 13.2.5.1. Market Size of Rosacea in United Kingdom
      • 13.2.5.2. Percentage Share of drugs marketed for Rosacea in United Kingdom
      • 13.2.5.3. Market Sales of Rosacea by Products in United Kingdom
      • 13.2.5.4. Analysis of Upcoming Therapies and their Impact on the Market
  • 13.3. Japan
    • 13.3.1. Market Size of Rosacea in Japan
    • 13.3.2. Percentage Share of drugs marketed for Rosacea in Japan
    • 13.3.3. Market Sales of Rosacea by Products in Japan
    • 13.3.4. Analysis of Upcoming Therapies and their Impact on the Market

14. Market Drivers

15. Market Barriers

16. Appendix

17. Report Methodology

  • 17.1. Sources

18. DelveInsight Capabilities

19. Disclaimer

20. About DelveInsight

Indication Specific

List of Tables

  • Table 1: Total Prevalent/Incident Cases of the Rosacea in 7MM
  • Table 2: Total Prevalent/Incident Cases of the Rosacea in 7MM by Countries
  • Table 3: Prevalent/Incident Cases of the Rosacea in United States (2016-2028)
  • Table 4: Sub-Type Specific cases of the Rosacea in United States (2016-2028)
  • Table 5: Sex- Specific Cases of the Rosacea in United States (2016-2028)
  • Table 6: Diagnosed Cases of the Rosacea in United States (2016-2028)
  • Table 7: Treatable Cases of the Rosacea in United States (2016-2028)
  • Table 8: Prevalent/Incident Cases of the Rosacea in Germany (2016-2028)
  • Table 9: Sub-Type Specific cases of the Rosacea in Germany (2016-2028)
  • Table 10: Sex- Specific Cases of the Rosacea in Germany (2016-2028)
  • Table 11: Diagnosed Cases of the Rosacea in Germany (2016-2028)
  • Table 12: Treatable Cases of the Rosacea in Germany (2016-2028)
  • Table 13: Prevalent/Incident Cases of the Rosacea in France (2016-2028)
  • Table 14: Sub-Type Specific cases of the Rosacea in France (2016-2028)
  • Table 15: Sex- Specific Cases of the Rosacea in France (2016-2028)
  • Table 16: Diagnosed Cases of the Rosacea in France (2016-2028)
  • Table 17: Treatable Cases of the Rosacea in France (2016-2028)
  • Table 18: Prevalent/Incident Cases of the Rosacea in Italy (2016-2028)
  • Table 19: Sub-Type Specific cases of the Rosacea in Italy (2016-2028)
  • Table 20: Sex- Specific Cases of the Rosacea in Italy (2016-2028)
  • Table 21: Diagnosed Cases of the Rosacea in Italy (2016-2028)
  • Table 22: Treatable Cases of the Rosacea in Italy (2016-2028)
  • Table 23: Prevalent/Incident Cases of the Rosacea in Spain (2016-2028)
  • Table 24: Sub-Type Specific cases of the Rosacea in Spain (2016-2028)
  • Table 25: Sex- Specific Cases of the Rosacea in Spain (2016-2028)
  • Table 26: Diagnosed Cases of the Rosacea in Spain (2016-2028)
  • Table 27: Treatable Cases of the Rosacea in Spain (2016-2028)
  • Table 28: Prevalent/Incident Cases of the Rosacea in UK (2016-2028)
  • Table 29: Sub-Type Specific cases of the Rosacea in UK (2016-2028)
  • Table 30: Sex- Specific Cases of the Rosacea in UK (2016-2028)
  • Table 31: Diagnosed Cases of the Rosacea in UK (2016-2028)
  • Table 32: Treatable Cases of the Rosacea in UK (2016-2028)
  • Table 33: Prevalent/Incident Cases of the Rosacea in Japan (2016-2028)
  • Table 34: Sub-Type Specific cases of the Rosacea in Japan (2016-2028)
  • Table 35: Sex- Specific Cases of the Rosacea in Japan (2016-2028)
  • Table 36: Diagnosed Cases of the Rosacea in Japan (2016-2028)
  • Table 37: Treatable Cases of the Rosacea in Japan (2016-2028)
  • Table 38: Marketed Therapies
  • Table 39: Emerging Therapies
  • Table 40: Key Cross Competition
  • Table 41:7MM- Market Size of Rosacea in USD MM (2016-2028)
  • Table 42:7MM- Market Share Rosacea by Therapies in USD MM (2016-2028)
  • Table 43:7MM- Market Sales of Rosacea by Therapies in USD MM (2016-2028)
  • Table 44: United States-Market Size of Rosacea in USD MM (2016-2028)
  • Table 45: United States-Market Share Rosacea by Therapies in USD MM (2016-2028)
  • Table 46: United States-Market Sales of Rosacea by Therapies in USD MM (2016-2028)
  • Table 47: Germany-Market Size of Rosacea in USD MM (2016-2028)
  • Table 48: Germany-Market Share Rosacea by Therapies in USD MM (2016-2028)
  • Table 49: Germany-Market Sales of Rosacea by Therapies in USD MM (2016-2028)
  • Table 50: France-Market Size of Rosacea in USD MM (2016-2028)
  • Table 51: France-Market Share Rosacea by Therapies in USD MM (2016-2028)
  • Table 52: France-Market Sales of Rosacea by Therapies in USD MM (2016-2028)
  • Table 53: Italy-Market Size of Rosacea in USD MM (2016-2028)
  • Table 54: Italy-Market Share Rosacea by Therapies in USD MM (2016-2028)
  • Table 55: Italy-Market Sales of Rosacea by Therapies in USD MM (2016-2028)
  • Table 56: Spain-Market Size of Rosacea in USD MM (2016-2028)
  • Table 57: Spain-Market Share Rosacea by Therapies in USD MM (2016-2028)
  • Table 58: Spain-Market Sales of Rosacea by Therapies in USD MM (2016-2028)
  • Table 59:UK-Market Size of Rosacea in USD MM (2016-2028)
  • Table 60:UK-Market Share Rosacea by Therapies in USD MM (2016-2028)
  • Table 61:UK-Market Sales of Rosacea by Therapies in USD MM (2016-2028)
  • Table 62: Japan-Market Size of Rosacea in USD MM (2016-2028)
  • Table 63: Japan-Market Share Rosacea by Therapies in USD MM (2016-2028)
  • Table 64: Japan-Market Sales of Rosacea by Therapies in USD MM (2016-2028)

List of Figures

  • Figure 1: Total Prevalent/Incident Cases of the Rosacea in 7MM
  • Figure 2: Total Prevalent/Incident Cases of the Rosacea in 7MM by Countries
  • Figure 3: Prevalent/Incident Cases of the Rosacea in United States (2016-2028)
  • Figure 4: Sub-Type Specific cases of the Rosacea in United States (2016-2028)
  • Figure 5: Sex- Specific Cases of the Rosacea in United States (2016-2028)
  • Figure 6: Diagnosed Cases of the Rosacea in United States (2016-2028)
  • Figure 7: Treatable Cases of the Rosacea in United States (2016-2028)
  • Figure 8: Prevalent/Incident Cases of the Rosacea in Germany (2016-2028)
  • Figure 9: Sub-Type Specific cases of the Rosacea in Germany (2016-2028)
  • Figure 10: Sex- Specific Cases of the Rosacea in Germany (2016-2028)
  • Figure 11: Diagnosed Cases of the Rosacea in Germany (2016-2028)
  • Figure 12: Treatable Cases of the Rosacea in Germany (2016-2028)
  • Figure 13: Prevalent/Incident Cases of the Rosacea in France (2016-2028)
  • Figure 14: Sub-Type Specific cases of the Rosacea in France (2016-2028)
  • Figure 15: Sex- Specific Cases of the Rosacea in France (2016-2028)
  • Figure 16: Diagnosed Cases of the Rosacea in France (2016-2028)
  • Figure 17: Treatable Cases of the Rosacea in France (2016-2028)
  • Figure 18: Prevalent/Incident Cases of the Rosacea in Italy (2016-2028)
  • Figure 19: Sub-Type Specific cases of the Rosacea in Italy (2016-2028)
  • Figure 20: Sex- Specific Cases of the Rosacea in Italy (2016-2028)
  • Figure 21: Diagnosed Cases of the Rosacea in Italy (2016-2028)
  • Figure 22: Treatable Cases of the Rosacea in Italy (2016-2028)
  • Figure 23: Prevalent/Incident Cases of the Rosacea in Spain (2016-2028)
  • Figure 24: Sub-Type Specific cases of the Rosacea in Spain (2016-2028)
  • Figure 25: Sex- Specific Cases of the Rosacea in Spain (2016-2028)
  • Figure 26: Diagnosed Cases of the Rosacea in Spain (2016-2028)
  • Figure 27: Treatable Cases of the Rosacea in Spain (2016-2028)
  • Figure 28: Prevalent/Incident Cases of the Rosacea in UK (2016-2028)
  • Figure 29: Sub-Type Specific cases of the Rosacea in UK (2016-2028)
  • Figure 30: Sex- Specific Cases of the Rosacea in UK (2016-2028)
  • Figure 31: Diagnosed Cases of the Rosacea in UK (2016-2028)
  • Figure 32: Treatable Cases of the Rosacea in UK (2016-2028)
  • Figure 33: Prevalent/Incident Cases of the Rosacea in Japan (2016-2028)
  • Figure 34: Sub-Type Specific cases of the Rosacea in Japan (2016-2028)
  • Figure 35: Sex- Specific Cases of the Rosacea in Japan (2016-2028)
  • Figure 36: Diagnosed Cases of the Rosacea in Japan (2016-2028)
  • Figure 37: Treatable Cases of the Rosacea in Japan (2016-2028)
  • Figure 38: Marketed Therapies
  • Figure 39: Emerging Therapies
  • Figure 40: Key Cross Competition
  • Figure 41:7MM- Market Size of Rosacea in USD MM (2016-2028)
  • Figure 42:7MM- Market Share Rosacea by Therapies in USD MM (2016-2028)
  • Figure 43:7MM- Market Sales of Rosacea by Therapies in USD MM (2016-2028)
  • Figure 44: United States-Market Size of Rosacea in USD MM (2016-2028)
  • Figure 45: United States-Market Share Rosacea by Therapies in USD MM (2016-2028)
  • Figure 46: United States-Market Sales of Rosacea by Therapies in USD MM (2016-2028)
  • Figure 47: Germany-Market Size of Rosacea in USD MM (2016-2028)
  • Figure 48: Germany-Market Share Rosacea by Therapies in USD MM (2016-2028)
  • Figure 49: Germany-Market Sales of Rosacea by Therapies in USD MM (2016-2028)
  • Figure 50: France-Market Size of Rosacea in USD MM (2016-2028)
  • Figure 51: France-Market Share Rosacea by Therapies in USD MM (2016-2028)
  • Figure 52: France-Market Sales of Rosacea by Therapies in USD MM (2016-2028)
  • Figure 53: Italy-Market Size of Rosacea in USD MM (2016-2028)
  • Figure 54: Italy-Market Share Rosacea by Therapies in USD MM (2016-2028)
  • Figure 55: Italy-Market Sales of Rosacea by Therapies in USD MM (2016-2028)
  • Figure 56: Spain-Market Size of Rosacea in USD MM (2016-2028)
  • Figure 57: Spain-Market Share Rosacea by Therapies in USD MM (2016-2028)
  • Figure 58: Spain-Market Sales of Rosacea by Therapies in USD MM (2016-2028)
  • Figure 59:UK-Market Size of Rosacea in USD MM (2016-2028)
  • Figure 60:UK-Market Share Rosacea by Therapies in USD MM (2016-2028)
  • Figure 61:UK-Market Sales of Rosacea by Therapies in USD MM (2016-2028)
  • Figure 62: Japan-Market Size of Rosacea in USD MM (2016-2028)
  • Figure 63: Japan-Market Share Rosacea by Therapies in USD MM (2016-2028)
  • Figure 64: Japan-Market Sales of Rosacea by Therapies in USD MM (2016-2028)